Whereas leptin appears not to hold promise as a stand-alone therapy for the treatment of common obesity, its combination with pramlintide (Amylin Pharmaceuticals) induces greater body weight loss in individuals of excess weight relative to treatment with either drug alone181,220. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.